Modality
Fusion Protein
MOA
PRMT5i
Target
IL-13
Pathway
DDR
PsoriasisSLE
Development Pipeline
Preclinical
~Feb 2017
→ ~May 2018
Phase 1
~Aug 2018
→ ~Nov 2019
Phase 2
Feb 2020
→ Oct 2028
Phase 2Current
NCT06497338
1,446 pts·SLE
2022-06→2028-10·Completed
NCT04184099
351 pts·SLE
2020-02→2028-07·Terminated
1,797 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-07-242.3y awayPh3 Readout· SLE
2028-10-152.5y awayPh3 Readout· SLE
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P2/3
Termina…
P2/3
Complet…
Catalysts
Ph3 Readout
2028-07-24 · 2.3y away
SLE
Ph3 Readout
2028-10-15 · 2.5y away
SLE
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06497338 | Phase 2/3 | SLE | Completed | 1446 | MRD |
| NCT04184099 | Phase 2/3 | SLE | Terminated | 351 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa |